img

Global Plasma-derived Factor VIII Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Plasma-derived Factor VIII Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

RECOMBINATE is recombinant Factor VIII, a clotting factor that is deficient in people with hemophilia A. 
The global Plasma-derived Factor VIII market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Plasma-derived Factor VIII is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Plasma-derived Factor VIII is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Plasma-derived Factor VIII is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Plasma-derived Factor VIII include Takeda, Octapharma, CSL, Grifols, Greencross, Kedrion, BPL, Hualan Bio and RAAS, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Plasma-derived Factor VIII, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Plasma-derived Factor VIII by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Plasma-derived Factor VIII market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Plasma-derived Factor VIII market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Takeda
Octapharma
CSL
Grifols
Greencross
Kedrion
BPL
Hualan Bio
RAAS
By Type
200IU
250IU
By Application
Hospital
Pharmacy
Sales by Region
North America
United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
UK
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Plasma-derived Factor VIII in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Plasma-derived Factor VIII manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Plasma-derived Factor VIII sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Plasma-derived Factor VIII Definition
1.2 Market by Type
1.2.1 Global Plasma-derived Factor VIII Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 200IU
1.2.3 250IU
1.3 Market Segment by Application
1.3.1 Global Plasma-derived Factor VIII Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Plasma-derived Factor VIII Sales
2.1 Global Plasma-derived Factor VIII Revenue Estimates and Forecasts 2018-2034
2.2 Global Plasma-derived Factor VIII Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Plasma-derived Factor VIII Revenue by Region
2.3.1 Global Plasma-derived Factor VIII Revenue by Region (2018-2024)
2.3.2 Global Plasma-derived Factor VIII Revenue by Region (2024-2034)
2.4 Global Plasma-derived Factor VIII Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Plasma-derived Factor VIII Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Plasma-derived Factor VIII Sales Quantity by Region
2.6.1 Global Plasma-derived Factor VIII Sales Quantity by Region (2018-2024)
2.6.2 Global Plasma-derived Factor VIII Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Plasma-derived Factor VIII Sales Quantity by Manufacturers
3.1.1 Global Plasma-derived Factor VIII Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Plasma-derived Factor VIII Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Plasma-derived Factor VIII Sales in 2022
3.2 Global Plasma-derived Factor VIII Revenue by Manufacturers
3.2.1 Global Plasma-derived Factor VIII Revenue by Manufacturers (2018-2024)
3.2.2 Global Plasma-derived Factor VIII Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Plasma-derived Factor VIII Revenue in 2022
3.3 Global Plasma-derived Factor VIII Sales Price by Manufacturers
3.4 Global Key Players of Plasma-derived Factor VIII, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Plasma-derived Factor VIII Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Plasma-derived Factor VIII, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Plasma-derived Factor VIII, Product Offered and Application
3.8 Global Key Manufacturers of Plasma-derived Factor VIII, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Plasma-derived Factor VIII Sales Quantity by Type
4.1.1 Global Plasma-derived Factor VIII Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Plasma-derived Factor VIII Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Plasma-derived Factor VIII Sales Quantity Market Share by Type (2018-2034)
4.2 Global Plasma-derived Factor VIII Revenue by Type
4.2.1 Global Plasma-derived Factor VIII Historical Revenue by Type (2018-2024)
4.2.2 Global Plasma-derived Factor VIII Forecasted Revenue by Type (2024-2034)
4.2.3 Global Plasma-derived Factor VIII Revenue Market Share by Type (2018-2034)
4.3 Global Plasma-derived Factor VIII Price by Type
4.3.1 Global Plasma-derived Factor VIII Price by Type (2018-2024)
4.3.2 Global Plasma-derived Factor VIII Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Plasma-derived Factor VIII Sales Quantity by Application
5.1.1 Global Plasma-derived Factor VIII Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Plasma-derived Factor VIII Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Plasma-derived Factor VIII Sales Quantity Market Share by Application (2018-2034)
5.2 Global Plasma-derived Factor VIII Revenue by Application
5.2.1 Global Plasma-derived Factor VIII Historical Revenue by Application (2018-2024)
5.2.2 Global Plasma-derived Factor VIII Forecasted Revenue by Application (2024-2034)
5.2.3 Global Plasma-derived Factor VIII Revenue Market Share by Application (2018-2034)
5.3 Global Plasma-derived Factor VIII Price by Application
5.3.1 Global Plasma-derived Factor VIII Price by Application (2018-2024)
5.3.2 Global Plasma-derived Factor VIII Price Forecast by Application (2024-2034)
6 North America
6.1 North America Plasma-derived Factor VIII Sales by Company
6.1.1 North America Plasma-derived Factor VIII Revenue by Company (2018-2024)
6.1.2 North America Plasma-derived Factor VIII Sales Quantity by Company (2018-2024)
6.2 North America Plasma-derived Factor VIII Market Size by Type
6.2.1 North America Plasma-derived Factor VIII Sales Quantity by Type (2018-2034)
6.2.2 North America Plasma-derived Factor VIII Revenue by Type (2018-2034)
6.3 North America Plasma-derived Factor VIII Market Size by Application
6.3.1 North America Plasma-derived Factor VIII Sales Quantity by Application (2018-2034)
6.3.2 North America Plasma-derived Factor VIII Revenue by Application (2018-2034)
6.4 North America Plasma-derived Factor VIII Market Size by Country
6.4.1 North America Plasma-derived Factor VIII Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Plasma-derived Factor VIII Revenue by Country (2018-2034)
6.4.3 North America Plasma-derived Factor VIII Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Plasma-derived Factor VIII Sales by Company
7.1.1 Europe Plasma-derived Factor VIII Sales Quantity by Company (2018-2024)
7.1.2 Europe Plasma-derived Factor VIII Revenue by Company (2018-2024)
7.2 Europe Plasma-derived Factor VIII Market Size by Type
7.2.1 Europe Plasma-derived Factor VIII Sales Quantity by Type (2018-2034)
7.2.2 Europe Plasma-derived Factor VIII Revenue by Type (2018-2034)
7.3 Europe Plasma-derived Factor VIII Market Size by Application
7.3.1 Europe Plasma-derived Factor VIII Sales Quantity by Application (2018-2034)
7.3.2 Europe Plasma-derived Factor VIII Revenue by Application (2018-2034)
7.4 Europe Plasma-derived Factor VIII Market Size by Country
7.4.1 Europe Plasma-derived Factor VIII Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Plasma-derived Factor VIII Revenue by Country (2018-2034)
7.4.3 Europe Plasma-derived Factor VIII Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 UK
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Plasma-derived Factor VIII Sales by Company
8.1.1 China Plasma-derived Factor VIII Sales Quantity by Company (2018-2024)
8.1.2 China Plasma-derived Factor VIII Revenue by Company (2018-2024)
8.2 China Plasma-derived Factor VIII Market Size by Type
8.2.1 China Plasma-derived Factor VIII Sales Quantity by Type (2018-2034)
8.2.2 China Plasma-derived Factor VIII Revenue by Type (2018-2034)
8.3 China Plasma-derived Factor VIII Market Size by Application
8.3.1 China Plasma-derived Factor VIII Sales Quantity by Application (2018-2034)
8.3.2 China Plasma-derived Factor VIII Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Plasma-derived Factor VIII Sales by Company
9.1.1 APAC Plasma-derived Factor VIII Sales Quantity by Company (2018-2024)
9.1.2 APAC Plasma-derived Factor VIII Revenue by Company (2018-2024)
9.2 APAC Plasma-derived Factor VIII Market Size by Type
9.2.1 APAC Plasma-derived Factor VIII Sales Quantity by Type (2018-2034)
9.2.2 APAC Plasma-derived Factor VIII Revenue by Type (2018-2034)
9.3 APAC Plasma-derived Factor VIII Market Size by Application
9.3.1 APAC Plasma-derived Factor VIII Sales Quantity by Application (2018-2034)
9.3.2 APAC Plasma-derived Factor VIII Revenue by Application (2018-2034)
9.4 APAC Plasma-derived Factor VIII Market Size by Region
9.4.1 APAC Plasma-derived Factor VIII Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Plasma-derived Factor VIII Revenue by Region (2018-2034)
9.4.3 APAC Plasma-derived Factor VIII Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Plasma-derived Factor VIII Sales by Company
10.1.1 Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Plasma-derived Factor VIII Market Size by Type
10.2.1 Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Plasma-derived Factor VIII Market Size by Application
10.3.1 Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Plasma-derived Factor VIII Market Size by Country
10.4.1 Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Takeda
11.1.1 Takeda Company Information
11.1.2 Takeda Overview
11.1.3 Takeda Plasma-derived Factor VIII Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Takeda Plasma-derived Factor VIII Products and Services
11.1.5 Takeda Plasma-derived Factor VIII SWOT Analysis
11.1.6 Takeda Recent Developments
11.2 Octapharma
11.2.1 Octapharma Company Information
11.2.2 Octapharma Overview
11.2.3 Octapharma Plasma-derived Factor VIII Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Octapharma Plasma-derived Factor VIII Products and Services
11.2.5 Octapharma Plasma-derived Factor VIII SWOT Analysis
11.2.6 Octapharma Recent Developments
11.3 CSL
11.3.1 CSL Company Information
11.3.2 CSL Overview
11.3.3 CSL Plasma-derived Factor VIII Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 CSL Plasma-derived Factor VIII Products and Services
11.3.5 CSL Plasma-derived Factor VIII SWOT Analysis
11.3.6 CSL Recent Developments
11.4 Grifols
11.4.1 Grifols Company Information
11.4.2 Grifols Overview
11.4.3 Grifols Plasma-derived Factor VIII Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Grifols Plasma-derived Factor VIII Products and Services
11.4.5 Grifols Plasma-derived Factor VIII SWOT Analysis
11.4.6 Grifols Recent Developments
11.5 Greencross
11.5.1 Greencross Company Information
11.5.2 Greencross Overview
11.5.3 Greencross Plasma-derived Factor VIII Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Greencross Plasma-derived Factor VIII Products and Services
11.5.5 Greencross Plasma-derived Factor VIII SWOT Analysis
11.5.6 Greencross Recent Developments
11.6 Kedrion
11.6.1 Kedrion Company Information
11.6.2 Kedrion Overview
11.6.3 Kedrion Plasma-derived Factor VIII Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Kedrion Plasma-derived Factor VIII Products and Services
11.6.5 Kedrion Plasma-derived Factor VIII SWOT Analysis
11.6.6 Kedrion Recent Developments
11.7 BPL
11.7.1 BPL Company Information
11.7.2 BPL Overview
11.7.3 BPL Plasma-derived Factor VIII Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 BPL Plasma-derived Factor VIII Products and Services
11.7.5 BPL Plasma-derived Factor VIII SWOT Analysis
11.7.6 BPL Recent Developments
11.8 Hualan Bio
11.8.1 Hualan Bio Company Information
11.8.2 Hualan Bio Overview
11.8.3 Hualan Bio Plasma-derived Factor VIII Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Hualan Bio Plasma-derived Factor VIII Products and Services
11.8.5 Hualan Bio Plasma-derived Factor VIII SWOT Analysis
11.8.6 Hualan Bio Recent Developments
11.9 RAAS
11.9.1 RAAS Company Information
11.9.2 RAAS Overview
11.9.3 RAAS Plasma-derived Factor VIII Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 RAAS Plasma-derived Factor VIII Products and Services
11.9.5 RAAS Plasma-derived Factor VIII SWOT Analysis
11.9.6 RAAS Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Plasma-derived Factor VIII Value Chain Analysis
12.2 Plasma-derived Factor VIII Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Plasma-derived Factor VIII Production Mode & Process
12.4 Plasma-derived Factor VIII Sales and Marketing
12.4.1 Plasma-derived Factor VIII Sales Channels
12.4.2 Plasma-derived Factor VIII Distributors
12.5 Plasma-derived Factor VIII Customers
13 Market Dynamics
13.1 Plasma-derived Factor VIII Industry Trends
13.2 Plasma-derived Factor VIII Market Drivers
13.3 Plasma-derived Factor VIII Market Challenges
13.4 Plasma-derived Factor VIII Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Plasma-derived Factor VIII Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of 200IU
Table 3. Major Manufacturers of 250IU
Table 4. Global Plasma-derived Factor VIII Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Plasma-derived Factor VIII Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Plasma-derived Factor VIII Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Plasma-derived Factor VIII Revenue Market Share by Region (2018-2024)
Table 8. Global Plasma-derived Factor VIII Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Plasma-derived Factor VIII Revenue Market Share by Region (2024-2034)
Table 10. Global Plasma-derived Factor VIII Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Plasma-derived Factor VIII Sales by Region (2018-2024) & (K Units)
Table 12. Global Plasma-derived Factor VIII Sales Market Share by Region (2018-2024)
Table 13. Global Plasma-derived Factor VIII Sales by Region (2024-2034) & (K Units)
Table 14. Global Plasma-derived Factor VIII Sales Market Share by Region (2024-2034)
Table 15. Global Plasma-derived Factor VIII Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Plasma-derived Factor VIII Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Plasma-derived Factor VIII Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Plasma-derived Factor VIII Revenue Share by Manufacturers (2018-2024)
Table 19. Global Plasma-derived Factor VIII Price by Manufacturers 2018-2024 (USD/Unit)
Table 20. Global Key Players of Plasma-derived Factor VIII, Industry Ranking, 2021 VS 2022
Table 21. Global Plasma-derived Factor VIII Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Plasma-derived Factor VIII by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Plasma-derived Factor VIII as of 2022)
Table 23. Global Key Manufacturers of Plasma-derived Factor VIII, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Plasma-derived Factor VIII, Product Offered and Application
Table 25. Global Key Manufacturers of Plasma-derived Factor VIII, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Plasma-derived Factor VIII Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Plasma-derived Factor VIII Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Plasma-derived Factor VIII Sales Quantity Share by Type (2018-2024)
Table 30. Global Plasma-derived Factor VIII Sales Quantity Share by Type (2024-2034)
Table 31. Global Plasma-derived Factor VIII Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Plasma-derived Factor VIII Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Plasma-derived Factor VIII Revenue Share by Type (2018-2024)
Table 34. Global Plasma-derived Factor VIII Revenue Share by Type (2024-2034)
Table 35. Plasma-derived Factor VIII Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Plasma-derived Factor VIII Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Plasma-derived Factor VIII Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Plasma-derived Factor VIII Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Plasma-derived Factor VIII Sales Quantity Share by Application (2018-2024)
Table 40. Global Plasma-derived Factor VIII Sales Quantity Share by Application (2024-2034)
Table 41. Global Plasma-derived Factor VIII Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Plasma-derived Factor VIII Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Plasma-derived Factor VIII Revenue Share by Application (2018-2024)
Table 44. Global Plasma-derived Factor VIII Revenue Share by Application (2024-2034)
Table 45. Plasma-derived Factor VIII Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Plasma-derived Factor VIII Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Plasma-derived Factor VIII Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Plasma-derived Factor VIII Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Plasma-derived Factor VIII Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Plasma-derived Factor VIII Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Plasma-derived Factor VIII Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Plasma-derived Factor VIII Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Plasma-derived Factor VIII Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Plasma-derived Factor VIII Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Plasma-derived Factor VIII Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Plasma-derived Factor VIII Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Plasma-derived Factor VIII Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Plasma-derived Factor VIII Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Plasma-derived Factor VIII Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Plasma-derived Factor VIII Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Plasma-derived Factor VIII Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Plasma-derived Factor VIII Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Plasma-derived Factor VIII Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Plasma-derived Factor VIII Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Plasma-derived Factor VIII Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Plasma-derived Factor VIII Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Plasma-derived Factor VIII Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Plasma-derived Factor VIII Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Plasma-derived Factor VIII Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Plasma-derived Factor VIII Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Plasma-derived Factor VIII Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Plasma-derived Factor VIII Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Plasma-derived Factor VIII Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Plasma-derived Factor VIII Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Plasma-derived Factor VIII Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Plasma-derived Factor VIII Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Plasma-derived Factor VIII Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Plasma-derived Factor VIII Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Plasma-derived Factor VIII Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Plasma-derived Factor VIII Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Plasma-derived Factor VIII Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Plasma-derived Factor VIII Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Plasma-derived Factor VIII Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Plasma-derived Factor VIII Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Plasma-derived Factor VIII Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Plasma-derived Factor VIII Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Plasma-derived Factor VIII Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Plasma-derived Factor VIII Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Plasma-derived Factor VIII Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Plasma-derived Factor VIII Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Plasma-derived Factor VIII Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Plasma-derived Factor VIII Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Plasma-derived Factor VIII Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Plasma-derived Factor VIII Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Plasma-derived Factor VIII Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Plasma-derived Factor VIII Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Plasma-derived Factor VIII Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Plasma-derived Factor VIII Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Plasma-derived Factor VIII Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Plasma-derived Factor VIII Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Plasma-derived Factor VIII Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Takeda Company Information
Table 118. Takeda Description and Overview
Table 119. Takeda Plasma-derived Factor VIII Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 120. Takeda Plasma-derived Factor VIII Product and Services
Table 121. Takeda Plasma-derived Factor VIII SWOT Analysis
Table 122. Takeda Recent Developments
Table 123. Octapharma Company Information
Table 124. Octapharma Description and Overview
Table 125. Octapharma Plasma-derived Factor VIII Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 126. Octapharma Plasma-derived Factor VIII Product and Services
Table 127. Octapharma Plasma-derived Factor VIII SWOT Analysis
Table 128. Octapharma Recent Developments
Table 129. CSL Company Information
Table 130. CSL Description and Overview
Table 131. CSL Plasma-derived Factor VIII Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 132. CSL Plasma-derived Factor VIII Product and Services
Table 133. CSL Plasma-derived Factor VIII SWOT Analysis
Table 134. CSL Recent Developments
Table 135. Grifols Company Information
Table 136. Grifols Description and Overview
Table 137. Grifols Plasma-derived Factor VIII Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 138. Grifols Plasma-derived Factor VIII Product and Services
Table 139. Grifols Plasma-derived Factor VIII SWOT Analysis
Table 140. Grifols Recent Developments
Table 141. Greencross Company Information
Table 142. Greencross Description and Overview
Table 143. Greencross Plasma-derived Factor VIII Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 144. Greencross Plasma-derived Factor VIII Product and Services
Table 145. Greencross Plasma-derived Factor VIII SWOT Analysis
Table 146. Greencross Recent Developments
Table 147. Kedrion Company Information
Table 148. Kedrion Description and Overview
Table 149. Kedrion Plasma-derived Factor VIII Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 150. Kedrion Plasma-derived Factor VIII Product and Services
Table 151. Kedrion Plasma-derived Factor VIII SWOT Analysis
Table 152. Kedrion Recent Developments
Table 153. BPL Company Information
Table 154. BPL Description and Overview
Table 155. BPL Plasma-derived Factor VIII Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 156. BPL Plasma-derived Factor VIII Product and Services
Table 157. BPL Plasma-derived Factor VIII SWOT Analysis
Table 158. BPL Recent Developments
Table 159. Hualan Bio Company Information
Table 160. Hualan Bio Description and Overview
Table 161. Hualan Bio Plasma-derived Factor VIII Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 162. Hualan Bio Plasma-derived Factor VIII Product and Services
Table 163. Hualan Bio Plasma-derived Factor VIII SWOT Analysis
Table 164. Hualan Bio Recent Developments
Table 165. RAAS Company Information
Table 166. RAAS Description and Overview
Table 167. RAAS Plasma-derived Factor VIII Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 168. RAAS Plasma-derived Factor VIII Product and Services
Table 169. RAAS Plasma-derived Factor VIII SWOT Analysis
Table 170. RAAS Recent Developments
Table 171. Key Raw Materials Lists
Table 172. Raw Materials Key Suppliers Lists
Table 173. Plasma-derived Factor VIII Distributors List
Table 174. Plasma-derived Factor VIII Customers List
Table 175. Plasma-derived Factor VIII Market Trends
Table 176. Plasma-derived Factor VIII Market Drivers
Table 177. Plasma-derived Factor VIII Market Challenges
Table 178. Plasma-derived Factor VIII Market Restraints
Table 179. Research Programs/Design for This Report
Table 180. Key Data Information from Secondary Sources
Table 181. Key Data Information from Primary Sources
List of Figures
Figure 1. Plasma-derived Factor VIII Product Picture
Figure 2. Global Plasma-derived Factor VIII Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Plasma-derived Factor VIII Market Share by Type in 2022 & 2034
Figure 4. 200IU Product Picture
Figure 5. 250IU Product Picture
Figure 6. Global Plasma-derived Factor VIII Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Plasma-derived Factor VIII Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Plasma-derived Factor VIII Report Years Considered
Figure 11. Global Plasma-derived Factor VIII Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 12. Global Plasma-derived Factor VIII Revenue 2018-2034 (US$ Million)
Figure 13. Global Plasma-derived Factor VIII Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 14. Global Plasma-derived Factor VIII Sales Quantity 2018-2034 (K Units)
Figure 15. Global Plasma-derived Factor VIII Sales Quantity Market Share by Region (2018-2024)
Figure 16. Global Plasma-derived Factor VIII Sales Quantity Market Share by Region (2024-2034)
Figure 17. North America Plasma-derived Factor VIII Sales Quantity YoY (2018-2034) & (K Units)
Figure 18. North America Plasma-derived Factor VIII Revenue YoY (2018-2034) & (US$ Million)
Figure 19. Europe Plasma-derived Factor VIII Sales Quantity YoY (2018-2034) & (K Units)
Figure 20. Europe Plasma-derived Factor VIII Revenue YoY (2018-2034) & (US$ Million)
Figure 21. China Plasma-derived Factor VIII Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. China Plasma-derived Factor VIII Revenue YoY (2018-2034) & (US$ Million)
Figure 23. APAC Plasma-derived Factor VIII Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. APAC Plasma-derived Factor VIII Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue YoY (2018-2034) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Plasma-derived Factor VIII Sales Quantity in 2022
Figure 28. The Top 10 and Top 5 Players Market Share by Plasma-derived Factor VIII Revenue in 2022
Figure 29. Plasma-derived Factor VIII Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Plasma-derived Factor VIII Sales Quantity Market Share by Type (2018-2034)
Figure 31. Global Plasma-derived Factor VIII Revenue Market Share by Type (2018-2034)
Figure 32. Global Plasma-derived Factor VIII Sales Quantity Market Share by Application (2018-2034)
Figure 33. Global Plasma-derived Factor VIII Revenue Market Share by Application (2018-2034)
Figure 34. North America Plasma-derived Factor VIII Revenue Market Share by Company in 2022
Figure 35. North America Plasma-derived Factor VIII Sales Quantity Market Share by Company in 2022
Figure 36. North America Plasma-derived Factor VIII Sales Quantity Market Share by Type (2018-2034)
Figure 37. North America Plasma-derived Factor VIII Revenue Market Share by Type (2018-2034)
Figure 38. North America Plasma-derived Factor VIII Sales Quantity Market Share by Application (2018-2034)
Figure 39. North America Plasma-derived Factor VIII Revenue Market Share by Application (2018-2034)
Figure 40. North America Plasma-derived Factor VIII Revenue Share by Country (2018-2034)
Figure 41. North America Plasma-derived Factor VIII Sales Quantity Share by Country (2018-2034)
Figure 42. United States Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Plasma-derived Factor VIII Sales Quantity Market Share by Company in 2022
Figure 45. Europe Plasma-derived Factor VIII Revenue Market Share by Company in 2022
Figure 46. Europe Plasma-derived Factor VIII Sales Quantity Market Share by Type (2018-2034)
Figure 47. Europe Plasma-derived Factor VIII Revenue Market Share by Type (2018-2034)
Figure 48. Europe Plasma-derived Factor VIII Sales Quantity Market Share by Application (2018-2034)
Figure 49. Europe Plasma-derived Factor VIII Revenue Market Share by Application (2018-2034)
Figure 50. Europe Plasma-derived Factor VIII Revenue Share by Country (2018-2034)
Figure 51. Europe Plasma-derived Factor VIII Sales Quantity Share by Country (2018-2034)
Figure 52. Germany Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 53. France Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 54. UK Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 55. Italy Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 56. Russia Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 57. China Plasma-derived Factor VIII Sales Quantity Market Share by Company in 2022
Figure 58. China Plasma-derived Factor VIII Revenue Market Share by Company in 2022
Figure 59. China Plasma-derived Factor VIII Sales Quantity Market Share by Type (2018-2034)
Figure 60. China Plasma-derived Factor VIII Revenue Market Share by Type (2018-2034)
Figure 61. China Plasma-derived Factor VIII Sales Quantity Market Share by Application (2018-2034)
Figure 62. China Plasma-derived Factor VIII Revenue Market Share by Application (2018-2034)
Figure 63. APAC Plasma-derived Factor VIII Sales Quantity Market Share by Company in 2022
Figure 64. APAC Plasma-derived Factor VIII Revenue Market Share by Company in 2022
Figure 65. APAC Plasma-derived Factor VIII Sales Quantity Market Share by Type (2018-2034)
Figure 66. APAC Plasma-derived Factor VIII Revenue Market Share by Type (2018-2034)
Figure 67. APAC Plasma-derived Factor VIII Sales Quantity Market Share by Application (2018-2034)
Figure 68. APAC Plasma-derived Factor VIII Revenue Market Share by Application (2018-2034)
Figure 69. APAC Plasma-derived Factor VIII Revenue Share by Region (2018-2034)
Figure 70. APAC Plasma-derived Factor VIII Sales Quantity Share by Region (2018-2034)
Figure 71. Japan Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 72. South Korea Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 73. China Taiwan Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 74. Southeast Asia Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 75. India Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 76. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity Market Share by Company in 2022
Figure 77. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity Market Share by Type (2018-2034)
Figure 79. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity Market Share by Application (2018-2034)
Figure 81. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Plasma-derived Factor VIII Sales Quantity Share by Country (2018-2034)
Figure 83. Middle East, Africa and Latin America Plasma-derived Factor VIII Revenue Share by Country (2018-2034)
Figure 84. Brazil Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 85. Mexico Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 86. Turkey Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 87. Israel Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 88. GCC Countries Plasma-derived Factor VIII Revenue (2018-2034) & (US$ Million)
Figure 89. Plasma-derived Factor VIII Value Chain
Figure 90. Plasma-derived Factor VIII Production Process
Figure 91. Channels of Distribution (Direct Vs Distribution)
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed